Research Article
The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome
Table 3
Characteristics of patients with ARDS and outcome of patients who were not treated with doranase alfa.
| | Characteristics | Number of patients (N = 6) | Outcome | Home | LTAC | Death/hospice |
| | Average age | 65 | | 1 | 1 | 4 | | Male | 4 | | 0 | 1 | 3 | | Female | 2 | | 1 | 0 | 1 |
| | Comorbidities | | | | | | | Hypothyroidism | 1 | | 1 | 0 | 0 | | CKD | 3 | | 0 | 1 | 2 | | HIV | 1 | | 0 | 0 | 1 | | CAD | 1 | | 0 | 0 | 1 |
| | Treatments | | | | | | | Dexamethasone | 3 | | 1 | 1 | 1 | | Solu-Medrol IV | 1 | | 0 | 0 | 1 | | Dexamethasone + remdesivir | 0 | | 0 | 0 | 0 | | Dexamethasone + plasma | 1 | | 0 | 0 | 1 | | Dexamethasone + plasma + hemolung | 1 | | 0 | 0 | 1 |
|
|
